Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson (JNJ) expands its agreement with BARDA, part of U.S. Department of Health and Human Services for accelerated development of a vaccine for the newly found coronavirus.

J&J (JNJ) Signs Deal With HHS to Develop Coronavirus Vaccine

Both parties will be funding the R&D costs for a new vaccine.

Johnson & Johnson Announces Partnership With U.S. government to Accelerate Coronavirus Vaccine Development

In the bid against other big pharma players to be the first to launch the coronavirus vaccine, Johnson & Johnson just announced a new collaboration that will double its efforts.

Johnson & Johnson Is Racing Against Time to Develop the First Coronavirus Vaccine

Discover

Altria

Public Storage

Texas Instruments

Exxon Mobil

These seven low-volatility stocks can help calm your nerves amid rising concerns regarding the coronavirus from China.

7 Low-Volatility Stocks to Buy In Jittery Times

JNJ stock topped a buy point. But several lawsuits claiming Johnson & Johnson baby powder caused cancer are weighing on shares.

JNJ Stock Continues To Hit Fresh Highs — Is It Time To Buy Shares?

J&J (JNJ) seeks approval for new Darzalex combo regimen in the United States to treat relapsed/refractory multiple myeloma patients who have received one to three prior lines of therapy.

J&J Files Application for Darzalex Label Expansion With FDA

Strong phase 3 trial results have prompted the healthcare giant to expand the use of Darzalex once again.

Johnson & Johnson Submits FDA Application for Multiple Myeloma Drug

PepsiCo

An off-price retailer, packaged foods giant, and healthcare juggernaut all generated consistent growth during previous recessions.

3 Top Stocks to  Recession - Proof Your Portfolio

The Thursday verdict came after the pharmaceutical giant’s CEO, Alex Gorsky, testified in the lawsuit last month, marking the first time he had taken the stand in a jury trial over the alleged dangers of its baby powder.

Johnson & Johnson hit with $750M verdict in baby powder lawsuit

Although JNJ stock has legal concerns that weigh on the narrative, the important point is to have the right focus; by that, I mean its stable dividends.
The post Can JNJ Stock Keep on Its Current Growth Track?

Can JNJ Stock Keep on Its Current Growth Track?

The pharmaceutical giant lost another major legal battle today.

Johnson & Johnson Hit With $750 Million Fine Over Baby Powder Legal Case

Johnson & Johnson was ordered on Thursday by a jury in a New Jersey court to pay punitive damages of $750 million to four plaintiffs who allege that the company's Baby Powder caused their cancer, according to a lawyer for the plaintiffs.

Johnson & Johnson ordered to pay $750 million in New Jersey talc case: lawyer

JNJ stock is on a scorching run in the markets recently, but the underlying fundamentals suggest that shares are close to fully pricing in the optimism.
The post Why Johnson & Johnson Is Deceptively Boring appeared first on InvestorPlace.

Why Johnson & Johnson Is Deceptively Boring

Novavax

Healthcare giant J&J and small biotech Novavax are both scrambling to develop coronavirus drugs. Which stock is the better pick?

Better Coronavirus Play: Johnson & Johnson vs. Novavax

A rare public meeting to discuss the testing of personal care products for asbestos was informative and disturbing.

FDA Shines a Spotlight on Asbestos Testing for Talc Products

JNJ stock has rallied as legal worries recede. Even at highs, J&J stock looks like an attractive pick for defensive-minded investors.

Johnson & Johnson Stock Looks Like a Safe Place to Hide Out

The healthcare stock's diversification remains one of its strengths.

Johnson & Johnson Keeps Growing Despite Ongoing Legal Woes

The company was found guilty of putting profits ahead of consumer safety.

Johnson & Johnson Ordered to Pay $344 Million for Deceptively Marketing Pelvic Mesh Product

Insys Therapeutics

McKesson

Mallinckrodt PLC

Bankruptcies reached a new high not seen since 2011, with opioid lawsuits playing a big role.

Biotech Bankruptcies Hit New Record in 2019

Despite slow revenue growth, the healthcare company has much to offer investors.

In a Mixed Quarter, Johnson & Johnson Shows Off Its Greatest Strength

Co-Diagnostics

Pulmatrix

Trillium Therapeutics

Vaxart

January has turned out great for biotech stocks thanks to the coronavirus outbreak as well as a general upbeat trend.

The Wining Sector & Its Top Stocks in Virus-Infected January

J&J (JNJ) is looking to develop a vaccine for the new coronavirus infection. Its drug Erleada's label is expanded to include new prostate cancer patient population in Europe.

J&J (JNJ) Plans to Develop Vaccine for New Coronavirus

One of the largest pharmaceutical companies in the world will leverage its antiviral research program to attack the rapidly spreading illness.

Johnson & Johnson Joins the Hunt for a Coronavirus Vaccine

Johnson & Johnson  announced Wednesday that it has initiated development of a vaccine against the new coronavirus, 2019nCoV, as part of its "multi-pronged" response to the outbreak of the deadly virus.

J&J begins development of coronavirus vaccine

The company's new depression treatment failed to win approval from NICE.

News for Johnson & Johnson Stock (JNJ)